

Ferring Pharma invests \$250M in new Hyderabad facility

02 July 2018 | News

Ferring plans to complete the project in three phases with a total proposed investment of \$250 million, with an estimated Rs 235 crores into the first phase itself.



Switzerland-based Ferring Pharmaceuticals has recently laid the foundation for its R&D laboratory and manufacturing facility at Genome Valley, Hyderabad. The new facility will also add to the group's global R&D capabilities and will cater to building a pool of novel research for emerging healthcare challenges around the world.

Ferring plans to complete the project in three phases with a total proposed investment of \$250 million, with an estimated Rs 235 crores into the first phase itself. Minister for Industries, IT, MA & UD, Government of Telangana, K Taraka Rama Rao and several dignitaries including senior TSIC officials took part in the ceremony.

Ferring Pharmaceuticals deals with reproductive medicine and women's health with strong presence in areas within gastroenterology and urology. The group has headquarters in St Prex, Switzerland with a portfolio of manufacturing facilities across Europe, North America, South America, China and India marketing its products in over 110 countries.